A Study to Assess the Safety of MEB-1170 in Healthy Subjects
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine the safety and tolerability of single and multiple ascending
oral doses of MEB-1170 in healthy subjects.
Secondary Objectives:
1. To determine the single and multiple oral dose pharmacokinetic profiles of MEB-1170 and
the primary metabolite, M373, in healthy subjects.
2. To determine the effect of food on the pharmacokinetic (PK) profile of a single oral
dose of MEB-1170 in healthy subjects.
3. To assess the pharmacodynamic (PD) response following single and multiple oral doses of
MEB-1170